NEW YORK — Reckitt Benckiser is seeking new creative behind its Mucinex brand, according to a report published in Ad Age Thursday.
Citing Kantar data, Ad Age reported RB placed $92 million behind Mucinex in 2012, when there was a strong and robust cough, cold and flu season helping to drive sales. Spending behind Mucinex in 2013 fell to $57 million.
RB CEO Rakesh Kapoor told analysts Wednesday that RB is "creating a new force in consumer health."
"We are allocating significant resources to consumer health, in terms of capabilities, R&D, brand equity investment and innovation, and we are seeing strong organic growth," he said. RB recently introduced Mucinex Allergy to store shelves.